Trial investigates negative predictive value of cystoscopic examinations in patients with bladder cancer
"The problem is that we are not very good at predicting who is not harboring any cancer in their bladder,” says Alexander Kutikov, MD, FACS.
In this video, Alexander Kutikov, MD, FACS, discusses his presentation, “Can systematic bladder sampling predict pT0?” which was part of the bladder cancer course at the 2021 Society of Urologic Oncology Annual Meeting. Kutikov is the chief of the division of urology and urologic oncology, professor in the department of surgical oncology, and the Roberta R. Scheller Chair in urologic oncology at the Fox Chase Cancer Center at Temple University in Philadelphia, Pennsylvania.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
